Director at Arbutus Biopharma (ABUS) receives 78,800 fully vested stock options

Rhea-AI Filing Summary

Arbutus Biopharma director Robert A. Beardsley was granted stock options to acquire 78,800 common shares. The options have an exercise price of $4.24 per share, are fully vested and exercisable as of the grant date, and expire on June 8, 2036. This is a compensation-related award, not an open-market purchase or sale.

Insights

Equity compensation analyst

Routine, fully vested option grant to a director, no open-market trading.

Arbutus Biopharma granted director Robert A. Beardsley stock options for 78,800 common shares at an exercise price of $4.24 per share. The grant is coded as an acquisition (A), reflecting compensation rather than a market trade.

The footnotes state the option is fully vested and exercisable on the grant date, with an expiration on June 8, 2036. No sales or exercises are reported here, and derivativeSummary is empty, suggesting this filing records the current option position from this grant only.

This type of award is a standard element of director compensation. Its economic impact depends on future stock performance and whether the director chooses to exercise before the 2036 expiration; those choices are not addressed in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Beardsley Robert A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	78,800	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 78,800 shares (Direct)

Footnotes (2)

1. F1. Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
2. F2. The option is fully vested and exercisable as of the date of the grant.

Key Figures

Option grant size: 78,800 options Exercise price: $4.24 per share Underlying shares: 78,800 shares +2 more

5 metrics

Option grant size 78,800 options Stock Option (Right to Buy) grant on June 8, 2026

Exercise price $4.24 per share Conversion or exercise price of the stock option

Underlying shares 78,800 shares Common shares underlying the option grant

Post-transaction derivative holdings 78,800 options Total derivative shares following the transaction

Option expiration June 8, 2036 Expiration date of the stock option grant

Key Terms

Stock Option (Right to Buy), exercise price, fully vested and exercisable, Grant, award, or other acquisition

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 4.2400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

fully vested and exercisable financial

"The option is fully vested and exercisable as of the date of the grant."

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/10/2026 - 04:06 PM Accepted by SEC EDGAR 06/10/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What did Arbutus Biopharma (ABUS) director Robert Beardsley report in this Form 4?

Robert Beardsley reported receiving a grant of stock options for 78,800 Arbutus Biopharma common shares. These options are a compensation-related award, not an open-market trade, and give him the right to buy shares at a fixed exercise price in the future.

How many Arbutus Biopharma (ABUS) shares are covered by the new option grant?

The option grant covers 78,800 underlying common shares of Arbutus Biopharma. This full amount represents his total derivative holdings from this grant after the transaction, according to the filing’s reported total shares following the transaction field.

What is the exercise price and term of Robert Beardsley’s Arbutus Biopharma options?

The stock options have an exercise price of $4.24 per Arbutus Biopharma common share and expire on June 8, 2036. This gives the director a long-dated right to purchase shares at that fixed price if future conditions make exercise attractive.

Are Robert Beardsley’s Arbutus Biopharma options immediately vested?

Yes. A footnote states the option is fully vested and exercisable as of the grant date. That means Beardsley does not have to wait for a vesting schedule and could exercise the options at any time before they expire in 2036, subject to applicable rules.

Does this Arbutus Biopharma Form 4 show any insider buying or selling in the market?

No open-market purchases or sales are reported. The filing shows only a compensation-related option grant coded as an acquisition (A). Transaction flags indicate no buy or sell activity, so this disclosure reflects an award, not trading in existing Arbutus Biopharma shares.

Is this Arbutus Biopharma (ABUS) Form 4 transaction routine or unusual?

The transaction appears routine, reflecting a typical director stock option grant. It is recorded as a grant or award acquisition, with no evidence of a Rule 10b5-1 sale or discretionary market trade, and fits common equity compensation practices for public company board members.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beardsley Robert A

(Last) (First) (Middle)

C/O ARBUTUS BIOPHARMA CORPORATION

701 VETERANS CIRCLE

(Street)

WARMINSTER PENNSYLVANIA 18974

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arbutus Biopharma Corp [ ABUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.24(1)	06/08/2026		A		78,800		06/08/2026(2)	06/08/2036	Common Shares	78,800	$0	78,800	D

Explanation of Responses:

1. Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.

2. The option is fully vested and exercisable as of the date of the grant.

Remarks:

	/s/ Tuan Nguyen as attorney-in-fact for Robert A Beardsley	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)